Lyme disease vaccine (recombinant ospa) Intramuscular and Polatuzumab vedotin
Determining the interaction of Lyme disease vaccine (recombinant ospa) Intramuscular and Polatuzumab vedotin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids. MANAGEMENT: The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease). References "Product Information. Lymerix (Lyme disease vaccine)." SmithKline Beecham, Philadelphia, PA.
Professional:GENERALLY AVOID: The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids.
MANAGEMENT: The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).
- "Product Information. Lymerix (Lyme disease vaccine)." SmithKline Beecham, Philadelphia, PA.
Generic Name: lyme disease vaccine
Brand name:
Synonyms: Lyme disease vaccine (recombinant ospa)
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lyme disease vaccine (recombinant ospa) Intramuscular-Polatuzumab Vedotin-piiq
- Lyme disease vaccine (recombinant ospa) Intramuscular-Polio vaccine, inactivated
- Lyme disease vaccine (recombinant ospa) Intramuscular-Poliovirus Vaccine (Inactivated)
- Lyme disease vaccine (recombinant ospa) Intramuscular-Poliovirus vaccine, inactivated Injection
- Lyme disease vaccine (recombinant ospa) Intramuscular-Polivy
- Lyme disease vaccine (recombinant ospa) Intramuscular-Polmon
- Polatuzumab vedotin-Lymepak
- Polatuzumab vedotin-Lymphocyte immune globulin, anti-thymocyte equine
- Polatuzumab vedotin-Lymphoseek
- Polatuzumab vedotin-Lynparza
- Polatuzumab vedotin-Lynparza (Olaparib Capsules)
- Polatuzumab vedotin-Lynparza (Olaparib Tablets)